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ABSTRACT 
BACKGROUND: It is recognized among providers, parents and health organizations 
that the current health care system is unprepared for a rising number of children 
diagnosed with Autism Spectrum Disorder (ASD) worldwide. Meanwhile, differences in 
mandated insurance coverage for ASD across the U.S. could drastically impact the 
diagnosis and treatment strategies chosen by providers and families. PURPOSE OF 
RESEARCH: The present case study aimed to review and compare policies and 
programs for children and adolescents with ASD in Pennsylvania (PA) and Georgia 
(GA), focusing on private insurance mandates. Additionally, the case study intended to 
identify and evaluate data sources that can be used to assess the implementation and 
impact of ASD insurance mandates in those states. METHODS: Key advocates and 
health agencies’ representatives were contacted to collaborate in the identification of the 
state regulated initiatives and potential data sources that track children and adolescents 
with ASD. Insurance enrollment, pharmacy care, health care service utilization, and cost 
of care were the indicators used to evaluate data sources in their ability to evaluate the 
impact of the insurance mandates. RESULTS: PA showed a more comprehensive 
insurance mandate and state-driven health-related initiatives for children and adolescents 
with ASD than GA. Among the nine data sources reviewed, including claims and survey 
data, none provide essential indicators for a comprehensive evaluation of the impact of 
the ASD insurance mandate in PA or GA. CONCLUSION: The case study indicated that 
for GA and PA, ASD policy tracking and evaluation can be accomplished with some of 
the currently available data sources, however, important gaps in the surveillance of ASD-
related outcomes exist. Thus, the study suggested that efforts towards more 
comprehensive data sources across all states is needed in order to evaluate ASD 
initiatives that inform ASD related- health policy and programs.   
KEYWORDS: Evaluation Studies; Child Development Disorders, Pervasive; Insurance 
Coverage; Data Collection; Pennsylvania; Georgia.      
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CHAPTER I 
 
INTRODUCTION  
 
Autism spectrum disorder (ASD) is defined as an aggregation of diagnoses that 
were previously considered separate conditions: Autistic Disorder, Asperger's Disorder, 
Childhood Disintegrative Disorder, and Pervasive Developmental Disorder, Not 
Otherwise Specified. A typical ASD patient presents signs of deficits in communication 
and social skills during early childhood. The prevalence of ASD has increased over the 
past several decades. In 2000, 1 in 150 children had prevalent ASD and this increased to 
1 in 68 children in 2010, which has caused significant concern among the public health 
community (Baio, 2014).  
The World Health Organization (WHO) released a meeting report on Autism 
Spectrum Disorder (ASD) and other developmental disabilities that intended to raise 
awareness and motivate “…innovative, integrated approaches for implementation of 
feasible, effective and sustainable intervention programs” (WHO, 2013). Health 
providers and parents recognize that the available health care system is unprepared in 
providing care to individuals with ASD. Even in nations with advanced care for ASD, 
there is an urgent need for consensus regarding the best approach to promote health in 
this population.  
Because the biological mechanisms of ASD remain uncertain and a wide range of 
signs and symptoms encompasses ASD diagnosis, identifying treatment options is a 
challenging process for families, and the healthcare providers. Thus, building evidence-
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based practices for ASD is the current focus of advocacy organizations and government 
agencies. The use of medication (Kumar et al., 2012) and early behavioral (Heyvaert et 
al., 2014) interventions have been the most traditional areas explored as “best practices”. 
Yet, some common treatments continue to be recommended without an assessment for 
the safety of the use in treating ASD (Schubar et al, 2014).  
Current differences in mandated insurance coverage for ASD across the U.S. 
could drastically impact the treatment chosen by providers and families (Stein et al., 
2012).  Therefore, a comparison of health services and drug prescription claims across 
states may help researchers understand the impact of different mandates in the uses of 
“best practices” for treating ASD patients. As an example, Pennsylvania (PA), the 7th 
State to enact an ASD reform, passed one of the most comprehensive bills in the country 
in 2009 (The National Autism Association of Pennsylvania, 2008). Meanwhile, in 
Georgia (GA), the Autism insurance reform bills were first introduced in January of 2009 
and, after several years of intense debate in the Senate and the House, had finally been 
version signed by GA’s governor only in April of 2015 (Autism Speaks, 2015). 
The present study will closely review current mandates across the two previously 
mentioned states and the available data sources to potentially assess how policy may 
impact diagnosis and treatment of ASD.  Health agencies, researchers and policymakers 
will benefit from this project by highlighting the strengths and limitations of current ASD 
insurance mandates and describing the available data collections that may be used to 
evaluate these practices and highlight in available data. Consequently, future research 
questions could be answered more objectively and gaps in the available data could be 
considered and addressed. 
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CHAPTER II 
LITERATURE REVIEW 
 
Definition and epidemiology of Autism Spectrum Disorder (ASD) 
 The 2013 Statistical Manual of Mental Disorders (DSM-IV) provides a guide 
medical providers for diagnosing psychiatric outcomes and specifies a relevant update on 
the criteria for ASD (APA, 2013). Thus, a patient could be considered an ASD case when 
diagnosed within any four distinct disorders: Autistic Disorder, Asperger's Disorder, 
Childhood Disintegrative Disorder, and Pervasive Developmental Disorder, Not 
Otherwise Specified. A comprehensive range of signs and symptoms are used for a more 
accurate recognition of cases, which may have a direct impact in the measurement of 
incidence in the population. Frequently, a typical Autism Spectrum case includes deficits 
in communication and social skills that are perceived during early childhood and that 
may also show different levels of severity.      
To date, there has been no single factor implicated as a cause of ASD. In fact, 
research has suggested that there is a multiple factor causal model, that includes genetics 
(Huquet et al., 2013), environmental factors (Durkin et al., 2008) and their interaction 
(Kinney et al., 2010).  Therefore, identifying specific risk factors for the prevention of 
ASD is still an area that is being carefully investigated. Furthermore, there is also no 
single test that can accurately diagnose ASD. The proper screening and early diagnoses 
of ASD depends on continuous and careful observation by caregivers and providers as 
well as a public access to information regarding ASD characteristics. The implementation 
of the ‘Learn the signs Act early’ campaign in U.S. has demonstrated a significant shift in 
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early detection of ASD through increasing knowledge about monitoring among parents 
and healthcare providers (Daniel et al., 2009).  
Worldwide, the prevalence of ASD has varied drastically since the beginning of 
its initial identification as a separate condition in late 60’s. Elsabbagh et al. (2012) 
reviewed international studies on ASD prevalence and stated that due to the stigma and 
structural barriers, low and middle income countries persist with ineffective surveillance 
systems for ASD. Therefore, the estimation of a current global median of 62 cases per 
10000 people is possibly underestimated. Higher rates of ASD in the U.S. and European 
countries when compared with the rest of the world could largely be a result of 
methodological differences in the diagnosis and reporting of ASD (Zaroff & Uhm, 2012). 
However, the main discussion across countries is regarding the increase in ASD 
incidence rates and the concern about the best practices for diagnoses and treatment.  
The exponential growth in ASD prevalence in the U.S. since 2000 has been only 
partly attributed to updates in the diagnostic criteria (Kim et al., 2014).  Associated with 
changes in diagnosis, awareness of ASD among the general public and providers and 
increase in parental age (Liu et al., 2010) are estimated to correspond in nearly 50% of 
the increase in ASD prevalence. The other half of the exponential increase in the number 
of ASD cases remains unexplained and continuous to be the subject of numerous 
researchers (Buttar, 2014; Nemirovsky et al., 2015; James, 2014) 
The epidemiology of ASD indicates that prevalence is higher among boys than 
girls, with the first diagnosis often happening around age 4 (Baio, 2014), and ASD is 
often comorbid with other mental health disorders (Levy et al., 2010). The previous 
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relationship found between ASD and socioeconomic factors was recognized to be the 
consequence of a social class bias in the service utilization among U.S. residents (Bhasin, 
& Schendel, 2007). Research focused on ethnic differences in the prevalence of ASD 
cases were almost exclusively conducted in the U.S. and suggested a higher risk among 
white Americans when compared with other ethnicities (Palmer, 2010). Among 
childhood mental and behavioral disorders in the U.S, ASD is one of the most frequent 
and debilitating (CDC, 2013; Matson et al., 2008). 
Best practices in ASD treatment 
Accurate and early diagnosis of ASD is considered an important first step for 
choosing an effective treatment plan, which could vary drastically among individuals and 
age groups. The key challenge is in promoting interventions that reduce the morbidity 
associated with ASD and simultaneously improve well-being, which necessarily includes 
independence and socialization of ASD patients throughout their lives.  When treating 
patients with ASD, a group of characteristics needs to be considered and assessed 
appropriately: community interaction, learning progress, self-care abilities, 
communication, co-occurrence of mental disorders, and other health-related issues 
(Mannion & Leader, 2013; Farmer & Aman, 2011). Because of the complexity of these 
group of characteristics that define ASD, treatment approaches tend to target in one or 
two of specific aspects (Patterson et al., 2012). 
Recently, McLeod et al. (2015) conducted a systematic review and found that 
limited literature existed on the efficacy of interventions for the ASD population. 
Because of this finding, the authors highlighted the need to consolidate evidence-based 
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interventions for ASD as a priority for health providers, educators, and caregivers.  To be 
considered evidence-based, an approach should promote “the integration of the best 
available research with clinical expertise in the context of patient characteristics, culture, 
and preferences” (APA, 2001). A consensus publication from the Missouri Autism 
Guidelines Initiative (2012) also focused on the reviewing evidence-based practices 
across the U.S. to provide an updated and improved guide from a systematic to an 
individual perspective of the treatment. This initiative assumes that “…providers need 
up-to-date information about intervention choices” and that government agencies should 
be in charge of building collaborations for the best exploration of those interventions.  
Research that has focused on addressing early intervention for children under 3 
years old has become popular and followed the current recommendation of ideal early 
detection of ASD cases. An extensive use of weekly therapy with several therapists and 
encouraging the parents’ constant participation are common among different treatment 
approaches in young children with ASD (Matson & Konst, 2014). Debates have 
suggested that influences of early treatments have the potential of “shaping the brain to 
be receptive to the social world, and in doing so, preventing or mitigating the symptoms 
and severity associated with ASD” (Sullivan et al., 2014). Yet, there is little evidence 
available regarding verified indications of how early interventions impact long term 
health outcomes for children with ASD.  
Pharmacological approach have played an important role in the design of 
treatment plans for ASD (Coury et al, 2012).Medications often support the management 
of more severe and comorbidity-related symptoms and should be considered as a 
supplementary treatment option. Drugs don’t cure or prevent the occurrence of the core 
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symptomatology and are highly associated with deleterious side effects, for which ASD 
patients are more vulnerable. Those medications are often prescribed  for  purposes that 
have not been approved by the Food and Drug Administration (FDA) for treating mental 
disorders in children and adolescents (Devulapalli & Nasrallah, 2009).Meanwhile, 
existing research does not provide sufficient, reliable and methodologically strong 
evidence regarding the effectiveness and safety of the drugs (Cauffield, 2013).  The use 
of medications and early behavioral treatment constantly frames the debates regarding the 
best practices for the management of ASD.  
Specialists and parents have been anticipating the emergence of more complete 
therapeutic strategies and multidirectional evaluations. In 2013, Autism Speaks (AS), a 
leading organization in science and advocacy features of ASD community, hosted their 
national conference entitled “Treating the Whole Person with Autism: Care across the 
Life” that highlighted the following: the inclusion of Medical Homes principles in the 
ASD treatment, the application of Community-Based Systems of Services in the 
coordination of care for ASD patients, and the construction of a more supportive health 
care delivery system to this population (Coury et al., 2014). Bringing the care to the 
community and promoting a systematic patient-centeredness approach could help address 
the needs of ASD patients more holistically.  
In previously implemented comprehensive treatment initiatives, ASD patients 
showed a higher level of satisfaction, experienced less unmet needs, and felt more 
empowered regarding their own care (Golnik et al., 2012). However, Knapp et al. (2013) 
discusses that children with behavioral health conditions often face several barriers in 
accessing services that are“…accessible, continuous, comprehensive, family-centered, 
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coordinated, compassionate, and culturally effective”. The vast range of symptoms and 
severity levels among ASD patients and the diversity of treatments available transform 
the individualized care into an urgent need. 
Antipsychotics and ASD treatment 
            Among drugs utilized in the management of ASD-related symptoms, 
antipsychotics are the most frequently studied; they were originally developed for the 
treatment of schizophrenia in the 1950’s. Antipsychotics reduce the dopamine effects in 
the brain, which are present in higher concentration in mentally-ill patients and are 
associated with irritability and psychotic episodes (Citrome, 2013). In general, two 
characteristics are currently used to describe antipsychotics: (1) first generation or 
conventional and (2) second generation or atypical. The use of first generation 
antipsychotics have a number of associated severe neural side effects (Peluso, 2012), 
including chronic involuntary body movements (dyskinesia). Among second generation 
agents, the side effects are less severe but still occur frequently, in particular weight gain 
(Almandil et al., 2013).  
            Currently, the only FDA-approved antipsychotics for the treatment of ASD are 
Risperidone and Aripiprazole, both second-generation agents. Risperidone was 
repeatedly tested using diverse methodological approaches and has been recognized to 
improve behaviors such as “irritability, aggression, self-injury and tantrums in autistic 
children and adolescents aged 5–16 years” (Malone, 2009). Aripiprazole, a drug that 
recently gained FDA approval, was verified to decrease disruptive symptoms in 
controlled trials involving children with ASD (Marcus et al., 2009). Increasing rates of 
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antipsychotic prescribing for very young children has been reported (Ofson, 2010) and in 
any given year nearly 40% of children with ASD receive an antipsychotic (Schubart, 
2014). 
Several challenges prevent the development of pharmaceutical treatment for ASD, 
which has led to an extensive body of research focused on other non-approved 
medications that will continue to be prescribed interchangeably. Antipsychotics have 
been tested less frequently among children and adolescents, which is due to safety 
concerns and apprehensions regarding the consequences of early exposure. Because of 
the common and often hazardous side effects, the prescription of Antipsychotics should 
be monitored closely, and when possible, avoiding chronic use. Furthermore, the lack of 
consensus across the country regarding the most effective drug strategy for ASD makes 
the monitoring of providers’ practices and their health-related consequences difficult. 
Service utilization and cost of ASD patients 
            The healthcare system availability and accessibility could have a direct impact in 
the treatment strategies chosen for ASD patients. Elsabbagh et al. (2012) found that 
Medicaid coverage was directly correlated with higher rates of service utilization among 
ASD patients, when compared with private insurance, due to differences in coverage of 
services. Early diagnosis is also more likely to occur in areas with a high intensity of 
specialized physicians (neurologists and psychiatrists and medical schools (Kalkbrenner 
et al., 2012).Parents also perceived the health care system as being unprepared for dealing 
with the needs of children with ASD in terms of accessibility and quality of services 
(Jabery et al., 2014), which could be more troubling in rural areas (Murphy, 2012). 
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Some unusual features associated with ASD also affect patterns of health care 
services utilization. The presence of other mental health conditions in addition to the 
ASD diagnoses has been associated with a more intense use of services, poorer insurance 
coverage, and health-related outcomes (Ahmedani, 2012). The use of these services also 
differs within ASD patients depending on age and race/ethnicity, but are typically higher 
relative to the general population (Broder-Fingert, 2013; Cidav, 2013). Family income 
was also a predictor of higher rates of physician visits, emergency rooms visits, and 
hospitalizations, when compared with non-cases (Wu et al., 2015). These obstacles often 
lead to less integrated and ineffective treatment plans during the early years, which has a 
direct impact on the transitioning to adulthood and the patient's long-term well-being.     
An increased demand for services among ASD patients is also associated with 
inflated health care costs. The cost of these services are covered in a variety of ways, 
including out of pocket, qualifying for publicly-financed (Medicaid) coverage, having 
private insurance, or relying on some combination of the three (Costlow et al., N.d.). 
Medical expenditures were predicted to be 4 to 6 times greater among children and 
adolescents with ASD when compared with those without an ASD diagnosis 
(Shimabukuro, 2008). During early childhood of individuals with ASD this healthcare 
cost is directly related with outpatient services utilization, while in older ages the health 
care cost is associated with the use of drugs and inpatient services (Shimabukuro, 2008). 
This prediction could be even more discrepant among patients enrolled in Medicaid 
(Wang, 2013). However, the cost associated with ASD goes beyond the health services 
utilization.  An ASD diagnosis can incur health care expenses in excess of $3,000 and an 
estited total cost (education, caregiver time, therapy, and others) of $17, 081 per year 
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(Lavelleet al., 2014). Chiara et al. reported that for each additional [ASD related] 
symptom reported was associated with $1,400 increase in costs per individual.      
Public Health policies for ASD in the U.S. 
            Since early 2000’s in the U.S., public health policies related with ASD have 
received increased attention. At the federal level, enacting of the Children’s Health Act of 
2000 and the Combating Autism Act in 2006 are significant initiatives that support 
awareness, surveillance, research, training, and advocacy of ASD. More recently, The 
Autism Collaboration, Accountability, Research, Education, and Support (CARES) Act 
of 2014 expanded provisions of previous congressional bills by including the needs of 
transitioning ASD youth. Other bills that focus on rebuilding access and delivery of care, 
such as The Affordable Care Act (ACA), also include provisions that address several 
unmet needs of ASD and related conditions (Golden et al., 2014).  
The U.S. Federalism model leaves states in a leadership position for the decision-
making process of many public health related policies. The National Conference of State 
Legislatures commented in 2012 that “Several states have developed task forces or 
commissions to further study autism issues.” Johnson et al. (2015) reviewed that policies 
in the state level translate local values and that could be a key cause for differences in the 
effectiveness of healthcare systems nationwide in addressing needs of ASD patients. 
Rzhetsky et al. (2014) suggested, in the attempt to build a framework for factors that 
affect ASD incidences in U.S. states, that “…the effect of state-level regulations [public 
health policies] involving ASD appeared relatively large in magnitude…”. 
12 
 
Insurance coverage could be a primary obstacle for the broader application of best 
practices in the management of ASD-related symptoms (Stein et al., 2012). Thus, many 
states have focused efforts in ASD-related insurance reforms in an attempt to decrease 
healthcare barriers for patients and intensify the financial contribution of states to the cost 
of ASD treatment. Since Indiana’s first law in 2001, 37 other states and 2 territories have 
enacted ASD-related insurance policies (Autism Speaks, 2015). However, the terms of 
coverage and eligibility criteria vary drastically within states, which could also have a 
direct impact in treatment patterns. Other states provide limited Autism mandates or 
include ASD patients in policies for mental health illness coverage (ASHA, 2015).    
ASD in Pennsylvania and Georgia 
The primary aim of the Autism and Developmental Disabilities Monitoring 
(ADDM) Network is to understand Autism and other disabilities regarding their 
occurrence and characteristics in the U.S. (CDC, 2009). It is a program funded by Center 
for Disease Control and Prevention (CDC) and consists of 16 tracking sites, including 
GA and PA. For the surveillance year of 2006, using heath records, PA found a 
prevalence of 8.4 ASD cases per 1,000 children aged 8 years old. For GA, using both 
health and education records, found a prevalence of 12 ASD cases per 1,000 children 
aged 8 years old. In the same report, those states discovered a similar median of age of 
first ASD detection (52 and 53 months). However, in the years following the first of 
ADDM surveillance, Pennsylvania and Georgia showed some differences in initiatives 
for the policy and management of ASD.  
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In 2008, PA passed a comprehensive bill (HB 1150) that requires both private 
insurances programs and medical assistance programs to cover specific behavioral 
therapy for ASD patients. Those covered benefits are copped at $36,000 a year and are 
applied to individuals with ASD aged 21 years old or younger. The Pennsylvania Autism 
Insurance Act, also known as Act 62, has no lifetime benefits caps or visit limits. PA also 
chose to expand the Medicaid program and to implement propositions of the ACA that 
impact the ASD community as a whole.  For example, ASD patients have guaranteed 
coverage of minimal health benefits, including behavioral health treatment with no 
lifetime or annual dollar caps (Bagley& Levy, 2014).    
GA very recently passed an ASD insurance reform. In 2009, the first time an ASD 
insurance bill (called Ava's law) was proposed in GA, the House voted against it, 
suggesting a need for an intense review of its propositions. In that bill, ASD-related 
services would covered for up to $35,000 a year under Ava’s Law (SB 397), which 
would not have been provided for patients covered by Medicaid. Currently, politicians 
and advocate groups continue to disagree on other provisions of the proposed bill, such as 
the use of therapeutic cannabis and the requirements for small companies, which has 
delayed its enactment. Meanwhile, the Medicaid program was not expanded in GA after 
the ACA came into effect in 2014. However, other ACA provisions that improve access 
to care, such as guaranteed coverage for individuals with pre-existing conditions, were 
adopted in GA and have the potential to positively impact many underserved groups such 
as ASD patients. 
Purpose of Capstone case study 
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A common concern among researchers, providers, and families who have a verted 
interest in the care of children and adolescent with ASD is identifying best practices for 
treatment. Currently, scientific studies on the effectiveness and quality of several 
pharmacological and non-pharmacological approaches are still underway. Thus, 
identifying current insurance and policy mandates for diagnosing, treating and managing 
children and adolescents with ASD is critical to understand current trends in a range of 
aspects related with ASD. This information is also critical for evaluating the impact of 
ASD practices and policies. Continuous monitoring and evaluation of policy coverage for 
ASD diagnosis and treatment is standard public health practice. 
A primary goal of the current case study is to provide a comprehensive summary 
of the available information regarding how children and adolescents with ASD are 
diagnosed, treated, and managed, and what data systems would be used to track public 
health policies for ASD. Additionally, data sources that can be used to assess the impact 
of ASD policies will be identified and evaluated.  To conduct this case study, two states 
with different insurance coverage mandates for ASD were identified: PA and GA. Three 
objectives guide this case study: 1) Compare and contrast ASD insurance coverage 
policies for two states, 2) Identify and evaluate data sources for tracking ASD diagnosis 
and treatment policies, 3) Identify and evaluate data sources that could assess the 
population-level impact of ASD policies and programs for a wide-range of ASD-related 
outcomes.  The present case study provides groundwork for future studies focused on 
health services utilization, prescription drugs and insurance coverage among children and 
adolescents with ASD. 
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Figure 1. CDC's recommended framework for program evaluation 
CHAPTER III 
METHODS AND RESULTS 
The present case study utilized the Framework for Program Evaluation in Public 
Health (CDC, 1999) during the construction of the methods to evaluate ASD-related 
policies and track data sources.  The CDC’s framework states that key steps for a strong 
evaluation (Figure 1) are interdependent and should be adapted to the program’s needs. 
CDC understands the idea of program as “any organized public health action”, such as 
the development and implementation of the ASD insurance mandate. The present case 
study was designed to serve as a component of a more comprehensive process evaluation 
of the impact of ASD insurance mandates in health indicators and outcomes of children 
and adolescents with ASD. 
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Identification of U.S. states with different insurance coverage mandates for ASD 
In 2014, Autism Speaks launched the “State Initiative Maps” (Figure 1), which 
reviewed the current status of ASD insurance mandate policies nationwide. For the 
purpose of this case study, two states were selected based on discrepancies in main terms 
of their ASD legislation (age group coverage, limit per year, and applicable groups) and 
because surveillance data was available for both of them from the Autism and 
Developmental Disabilities Monitoring (ADDM) research site. Thus, PA will be 
considered representative of the group of “States with Autism Insurance Reform Laws” 
and GA “States with endorsed Autism insurance reform bills.” This map was updated 
before the passage of GA’s mandate in April of 2015, but will still be considered for this 
case study because of the terms of these mandate have not yet been implemented.  
Figure 2. States Initiatives Map (Autism Speaks, 2014) 
  
States with Autism 
Insurance Reform 
Laws 
States with endorsed 
Autism Insurance 
Reform Bills 
State Pursuing 
Autism Insurance 
Reform 
State Not Pursuing 
Insurance Reform 
Legislation 
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1) Comparison of states on ASD insurance coverage 
To provide an accurate review of public health policies involving ASD that could 
impact drugs and health service utilization in the selected states, the following online 
sources were examined: Pennsylvania’s Department of Health and Human Services and 
Georgia’s Behavioral Health and Developmental Disabilities, Department of Community 
Health, and Department of Public Health.  Furthermore, key advocates and health 
agencies’ representatives were contacted to provide insights on the policies and programs 
in place for Georgia and Pennsylvania. The following list of organizations voluntarily 
informed this study:  
1) Division of Birth Defects and Developmental Disabilities (CDC);  
2) Satcher Health Leadership Institute;  
3) Autism Speaks;  
4) Association of University Centers on Disabilities (AUCD);  
5) Morehouse Medical School;  
6) Emory Autism Center;  
7) Center for Leadership in Disability;  
8) The Center for Autism;  
9) Pennsylvania Department of Human Services;  
10)  Autism Services, Education, Resources and Training (ASERT).  
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In the early 2000’s, PA intensified their efforts to more explicitly address the 
needs of individuals with ASD (Table 1). Initially, the creation of The Autism Task Force 
resulted in the implementation of the PA Autism Census Project and the Bureau of 
Autism Services (BAS) (Table 1).  The BAS then conducted The PA Autism Needs 
Assessment and launched the Autism Services, Education, Resources and Training 
(ASERT) program (Table 2). PA also adopted Medicaid Waivers under the Home and 
Community Based Services (HCBS) program options that allow the provision of long 
term care services in home and community based settings. Under HCBS programs, the 
federal government "waives" Medical Assistance/Medicaid rules for institutional care in 
order for the state to use the same funds to provide supports and services for people in 
their own communities. Parents of children and adolescents may be eligible to apply for 
several waivers, but the Medicaid Waiver for Infants, Toddlers, and Families specifically 
targets the management of ASD in PA (Table 1). Since 1987, the Georgian interagency 
Babies Can't Wait (BCW) has provided early interventions and has been focusing its 
efforts on Autism during recent years (Table 1). In 2001, the HB 565 law required 
insurance plans in GA to include ASD in the same benefits group as those individuals 
with other neurological disorders (Table 1). GA also has adopted some HCBS Medicaid 
waivers that may impact the care of children and adolescents with ASD, specifically the 
Comprehensive Supports waiver program (Table 1). 
Table 1. Public Health policies and programs for children and adolescents with ASD 
in Pennsylvania and Georgia 
State Year Public Health policy or program 
PA 2003 The Autism Task Force 
Created by the Department of Public Welfare. Included over 250 family 
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members, providers, educators, administrators and researchers that 
developed a plan for a new system for individuals with ASD and their 
families. 
(PA Department of Public Welfare Commonwealth of Pennsylvania. Autism Task Force: Final Report. 
(2004). Retrieved from: https://www.paautism.org/) 
2005 Pennsylvania Autism Census Project 
First conducted by the Department of Public Welfare to estimate the 
number of individuals living with ASD in Pennsylvania and the 
demographic characteristics and scope of needs for ASD-related services 
and programs. The census was updated in 2013.   
(PA Department of Public Welfare, Bureau of Autism Services. Pennsylvania Autism Census Project: Final 
report. (2009). Retrieved from: http://www.dhs.state.pa.us/) 
2006 1915(c) HCBS waivers program  
Medicaid Waiver for Infants, Toddlers, and Families 
Provides services to children from 0-3 years old who are in need of Early 
Intervention services and require the level of care provided in an 
Intermediate Care Facility for Persons with Mental Retardation or Other 
Related Conditions (ICF/MR-ORC). Children eligible to apply should 
have family income limit of 300 % Federal Benefit Rate 
(Pennsylvania Dep. Of Human Services. Waiver Information. Retrieved from 
http://www.dhs.state.pa.us/learnaboutdhs/waiverinformation/infanttoddlersandfamilieswaiver/index.htm) 
2007 Bureau of Autism Services (BAS) 
Created as a recommendation of the Autism Task Force Administrated by 
the Department of Human Services.  Aims to develop and manage 
services and supports to improve the quality of life of individuals living 
with ASD and their families/caregivers. 
(Bureau of Autism Services. (n.d.). Retrieved March 8, 2015, from http://www.dhs.state.pa.us ) 
2008 Autism Services, Education, Resources and Training (ASERT) 
Maintained by the Bureau of Autism Services in a partnership with 
medical, research, and services centers. Intends to connect existing 
resources and key expertise to address regional gaps in effective services 
and supports. ASERT activities are driven by PA Autism Needs 
Assessment findings.  
 (ASERT Overview. (n.d.). Retrieved March 8, 2015, from http://www.paautism.org/en-
us/asert/asertoverview.aspx) 
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2008 Autism Insurance Act (Act 68) 
PA was the 7th state in the U.S. to enact an insurance regulation for 
individuals with ASD.  The bill requires health insurance policies and 
medical assistance programs to cover up to $36,000 for the diagnosis and 
treatment of ASD in individuals younger than 21 years of age. 
(Autism Speaks. SUMMARY OF PENNSYLVANIA AUTISM INSURANCE REFORM LAW 
PROVISIONS. 2009. Retrieved from: https://www.autismspeaks.org/advocacy/helpful-links/pennsylvania-
helpful-links) 
2011 PA Autism Needs Assessment 
Conducted by the Bureau of Autism Services and ASERT to have a 
deeper understanding, on a local level, of specific needs of children and 
adults across the lifespan. 
(PA Autism Needs Assessment: A Survey of Individuals and Families Living with Autism. (n.d.). Retrieved 
March 8, 2015, from http://www.paautism.org/resources ) 
GA 1987 Babies Can't Wait (BCW) 
BCW is a statewide interagency of early intervention services for 
children with disabilities such as ASD, their families, and providers. It 
was established in GA to follow requirements of the Individuals with 
Disabilities Education Act (1997).  
Georgia Department of Public Health. Babies Can’t Wait GA. Retrieved from: http://dph.georgia.gov/Babies-
Cant-Wait) 
2001   H.B. 565 
Under HB 565, health insurance plans that provide benefits for 
neurological disorders must cover the same benefits, including the scope 
of treatment for individuals diagnosed with ASD.  
(Georgia General Assembly. House Bill 565. Retrieved from: 
http://www.legis.ga.gov/Legislation/20012002/2929.pdf) 
2008 1915(c) HCBS waivers program  
Comprehensive Supports waiver (COMP) 
It was designed for people who need a full range of out-of home services 
or intensive in-home services. Community residential and alternative 
services are only available in the COMP waiver. The alternative services 
include Applied Behavioral Analysis and other therapies for ASD.  
(Adams D. 2009. Constructing a good life through Understanding the now and comp waivers, A Ready 
Reference for Families and Individuals with Disabilities. Retrieved from: http://www.dfmc-
georgia.org/resources/documents/now_and_comp_waivers.pdf) 
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2009 Study Committee on Autism 
The Study Committee aims to discuss issues related to availability, 
access, and affordability of health care insurance covering ASD. It was 
proposed by Sen. Tommie Williams, leader of the ASD Insurance bill 
proposal, through several committees since 2009.  
(Easter Seals, Inc.  2012 State Autism Profiles GEORGIA. 2012. Retrieved from: 
http://es.easterseals.com/site/DocServer/2012_Autism_Georgia.pdf?docID=155459) 
2015 Ava’s Law 
Ava’s Law was first introduced by Georgia’s Senate (SB 161) in 2009 to 
require full coverage of ASD treatment services for children aged 6 years 
old and younger. The final version was released in the General Assembly 
f 2015. The bill was approved by the House and Senate in 2015 and 
signed by GA’s Governor in early April of the same year. 
(Autism Speaks. Georgia Bill History. 2014. Retrieved from: https://www.autismspeaks.org/bill-
history/advocacy/georgia-bill-history; William, D. 2015. Autism bill gains final passage from General 
Assembly. Atlanta Business Chronicles Retrieved form:   
http://www.bizjournals.com/atlanta/blog/capitol_vision/2015/04/autism-bill-gains-final-passage-from-
general.html ) 
 
In 2008, PA passed the comprehensive Autism Insurance Act that mandated 
private insurance companies to cover services for individuals with ASD up to 21 years 
old (Table 2). PA’s mandate is applicable to individuals under large business plans (more 
than 50 employers), in PA Children's Health Insurance Program (CHIP), and to a limited 
extent the Medicaid program. In addition, there are no caps in the number of visits or a 
life-long benefit limit for individuals with ASD under the PA mandate. It is important to 
note that in PA, children and adolescents may be eligible for the Medical Assistance 
program (Medicaid) if meeting the income requirements or the Social Security 
Administration (SSA) definition of disability. The HB 1150 also established guidelines 
for children enrolled in Medical Assistance, PA Department of Public Welfare will cover 
the costs that exceed the Medicaid limit.  
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The first insurance mandate bill for individuals with ASD in GA, named Ava’s 
Law, was proposed in 2009 and targeted children up to 6 years old (Table 2). Recently, 
GA’s legislature postponed the passage of Ava’s Law for more than 2 years and the law 
in place is considered a conservative in terms of coverage by ASD advocate groups in the 
U.S., especially because of the limited age group included. A final version of the bill was 
passed in the General Assembly in late March of 2015 and the Governor’s signature in 
early April, during the World Autism Awareness Day. The coverage of behavioral health 
treatment, which is often denied by private insurance companies, is one of the main 
features of the bill passed in GA.  Ava’s Law does not include provisions that address 
services for individuals under the Medicaid program and, currently, individuals with 
ASD enrolled in Medicaid are covered by the HCBS waivers program.  
Table 2. State ASD insurance coverage mandate in Pennsylvania and Georgia 
 Pennsylvania Georgia 
Bill Autism Insurance Act 
(HB 1150) 
Ava’s Law  
(HB 309/SB 191/HB 559) 
Year of Enactment 2008 2015 
Age group coverage 0-21 year old  0-6 year old 
Benefit limit $36,000/year $30,000/year  
Applicable to small 
business and individual 
plans 
NO YES (over 10 members) 
Applicable to large 
business (51 member 
or more) 
YES YES 
Applicable to Medicaid 
enrollers  
YES NO 
Lifetime benefit limit NO YES ($200,000) 
Visits limit NO NO 
Services coverage Medically necessary services 
(1) Prescribed medications 
Medically necessary services 
(1) Prescribed medications 
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and related tests (2) 
Psychiatric care (3) 
Psychological care (4) 
Rehabilitative care, including 
applied behavior analysis (5) 
Speech, occupational and 
physical therapy 
and related tests (2) 
Psychiatric care (3) 
Psychological care (4) 
Rehabilitative care, including 
applied behavior analysis 
(5) Speech occupational and 
physical therapy 
 
2) Identification and comparison of data sources for tracking ASD insurance 
policies 
Indicators 
 In the process of identifying data sources that could track insurance policies for 
ASD in the selected states, the main resources used were Georgia State University 
Library research tool and librarians, CDC’s Nacional Center for Health Statistics, and 
informing organizations. Inclusion criteria for evaluating data sources in this case study 
include: (1) represent individuals or groups from PA and GA, (2) distinguish children and 
adolescents with an ASD diagnosis, and (3) track two or more indicator of the insurance 
policies for ASD. The indicators of interest included: insurance enrollment (private and 
public funding), drugs prescription and dispensing (pharmacy care), health care services 
utilization (ASD-related exams, psychiatric care, psychological care, rehabilitation care, 
and therapeutic care), and cost of care (Table 3) 
Table 3. Indicators of insurance policies used in the description of data sources 
Indicators Definition* 
Insurance enrollment  The data source identifies the type of insurance 
enrollment plan. Private and public insurance enrollers 
could be distinguished.    
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Drugs prescription and 
dispersion (pharmacy 
care) 
The data source provides information on drugs 
prescription and/or dispersion. The type of drug (generic 
or commercial IDs) is provided. Drugs used for the 
treatment of ASD-related symptoms could be identified.    
Health care service 
utilization* 
The data source provides information about health care 
services utilized. Setting, provider, and/or service 
provided could be accessed and discriminated as: 
(1) ASD-related exams: diagnostic assessment of autism 
spectrum disorders; 
(2) Psychiatric care: direct or consultative services 
provided by a physician who specializes in psychiatry; 
(3) Psychological care: direct or consultative services 
provided by a psychologist; 
(4)  Rehabilitative care: professional services and 
treatment programs, including applied behavioral 
analysis, provided by an autism service provider to 
produce socially significant improvements in human 
behavior or to prevent loss of attained skill or function; 
(5) Therapeutic care: services provided by speech 
language pathologists, occupational therapists or physical 
therapists 
Cost of care  The data source provides cost of health care service and 
pharmacy care prescribed and/or utilized. Copays may 
also be accessed.  
* Definitions were retrieved from the ASD insurance bills.    
Data sources 
The National Center for Health Statistics (NCHS) provides several public-use 
data sets. Considering the inclusion criteria for the present study, the data from the 
following NCHS’ studies were evaluated: the National Ambulatory Medical Care Survey 
(NAMCS), the National Hospital Ambulatory Medical Care Survey (NHAMCS), the 
National Health Interview Survey (NHIS Sample Child), National Survey of Children's 
Health (NSCH), and the National Survey of Children with Special Health Care Needs 
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(NS-CSHCN) (Table 4). The data sources found using GSU Library Tool (Statistical 
Information and Data on children and adolescents health) and suggested by the informing 
organizations were the Medicaid Analytic Extract (MAX), The Healthcare Cost and 
Utilization Project (HCUP State-Specific: Inpatient Databases, and Emergency 
Department Databases), The Medical Expenditure Panel Survey (MEPS 
Insurance/Employer and Medical Provider Components), and MarketScan databases 
(Medicaid and Commercial Claims and Encounters) (Table 4). Other data sources that 
track children and adolescents with ASD, such as data from the Study to Explore Early 
Development, the Autism and Developmental Disabilities Monitoring Network and PA 
Autism Census, were also proposed but not included in this analysis because insurance 
policy indicators were not included. Table 5 evaluates data sources in the capacity of 
monitored ASD insurance policies in Pennsylvania and Georgia using indicators 
described in Table 3.
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Table 4. Data sources that track ASD insurance policies’ indicators in Pennsylvania and Georgia 
Data source  
(Years released 
until date) 
Sponsored agency 
PA GA Insurance 
enrollment 
Drugs 
prescription 
Health care service Utilization Cost 
of 
Care 
Main limitations of the data source 
ASD-
related 
exams 
Psychic. 
Care 
Psycho. 
care 
Rehab. 
care 
Therap. 
care 
NAMCS 
(1993-2014) 
CDC/NCHS 
X* X* X X  X X    Only includes data related to office-based physicians’ 
visits. It is nationally representative survey data.   
NHAMCS 
(1993-2014) 
CDC/NCHS 
X* X* X X  X X    Only includes data related to ambulatory care services. 
It is nationally representative survey data.   
NHIS Sample 
child 
(1997-2014) 
CDC/NCHS 
X* X* X X  X X  X X**** It is a nationally survey data.   
NSCH 
(2003-2011/12) 
USDHHS, HRSA, 
MCHB 
X X X X X*** X X X X X**** It is a nationally telephone surveys data. 
NS-CSHCN 
(2001-2009/10) 
USDHHS, HRSA, 
MCHB 
X X X X X X X X X X**** It is a nationally telephone surveys data. 
MAX 
(2002-present) 
MMIS 
X X X** X X*** X X X X X Only includes Medicaid and CHIP enrollers. Does not 
collect data on exams and therapies.   
HCUP State-
Specific 
Databases 
(1990-2012) 
AHRQ 
X X X X  X    X Only collects data related to hospitals and emergency 
care.  
MEPS 
(1996-2014) 
USDHHS/CDC 
X X X X  X X X X X It is nationally representative survey data.   
MarketScan  
(1994-2014) 
TRUVEN®  
X X X X X*** X X  X X Only collects data related with services coverage 
under insurance. Behavioral therapies are often 
unrepresented.  
*Nationally representative data sets that provide ZIPCODE and could be subgrouped for each state.  ** Includes Medicaid and CHIP enrollers. 
*** Provide information on general mental health/behavioral exams.  **** Provide information regarding general expenditure or cost barriers
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3) Description of data sources that can assess the state-level impact of insurance 
policies in ASD-related outcomes 
 MAX, HCUP and MarketScan are claims data sources that gather information 
from medically attended visits in different care settings (Table 4). One advantage of 
claims data is the reliability of the outcomes (it is based on medical records) and some 
disadvantage are the fragile generalizability (could only provide inferences to a specific 
group) and the fact that ASD diagnosis is not commonly done in a systematic manner. 
MAX data are collected in the state’s Medicaid Management Information System 
(MMIS), which is based on different states’ Medicaid programs and reported to the 
federal statistical system. MAX contains variables from inpatient admissions, long-term 
care, pharmacy, and other medical services coded in the Healthcare Common Procedure 
Coding System (HCPCS). Examples of variables that could track ASD insurance policy 
indicators are: Medicaid/CHIP enrollment plan, provider type, billing information 
(deductible, third party payment, coinsurance, etc.), mental health admissions, psychiatric 
services, therapies, early periodic screening, and drugs prescribed. 
The collection of HCUP State-Specific Databases is sponsored by the Agency for 
Healthcare Research and Quality (AHRQ) and provides claims related to hospitalizations 
(even psychiatric) and emergency care. HCUP contain information regarding insurance 
coverage, codes to all services provided during the hospital visit, and their respective 
cost. However, because it does not encompass primary care and specialty setting, HCUP 
lacks the tracking of claims related to those services (ASD-related exams and 
psychological, rehabilitative, and therapeutic care). Lastly, MarketScan offers the largest 
convenience sample available among private databases for individuals under large 
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employer-provided health insurance in the U.S. It is more comprehensive because it 
captures the full variety of care in almost all settings (physician office visits, hospital 
stays, and detailed pharmacy care). MarketScan could also allow the longitudinal 
tracking of claims in a same group of individuals. Conversely, because it only computes 
services covered by insurance policies, it cannot track the use of services that are 
commonly not covered, such as behavioral services.    
 The other data sources reviewed in the present study collected data through 
surveys. This type of data present better external validity (better to draw conclusions 
about the population) than claims data but provides less specific outcomes to the target 
population. NAMCS and NHAMCS have a similar annually sampling approach. NAMCS 
track visits to non-federal employed office-based physicians, who completed the survey. 
NHAMCS collect data on the utilization and provision of ambulatory care services by the 
implementation of a patient record that is filled by the facility’s staff. Both data sources 
include insurance coverage type and drugs prescribed and identify mental health services 
by the collection of data on the type of facility, provider, and treatment (such as 
psychotherapy or mental health counseling).  
 The NSCH and NS-CSHCN are both telephone surveys sponsored by a 
cooperative agreement from the U.S. Department of Health and Human Services 
(USDHHS), Health Resources and Services Administration (HRSA), Maternal and Child 
Health Bureau (MCHB) and represent non-institutionalized children ages 0-17 in the 
national and state level. Those datasets include insurance and health care access, 
prescription drugs, mental health service utilization (including behavioral services), and 
questions regarding additional costs for services not covered under the insurance plan. 
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The NSCH serves as a supplement for the NS-CSHCN. The latter includes additional 
information regarding access to coordination of care, patient-centered services, adequacy 
of healthcare coverage, and children with disabilities’ unmet needs (including financial 
barriers).   
NHIS data is collected through an annual cross-sectional household interview 
survey and serves as the principal source of information for a broad range of health topics 
in the U.S. The child section of the NHIS Sample reports health-related events involving 
children living in the household. Questions regarding the insurance coverage, mental 
health related drugs prescription, access to mental health providers and therapeutic care 
are included. By tracking financial barriers in accessing to specific ASD-related services, 
this sample represents a subjective reports on cost of care. Finally, MEPS, which is a 
subsample of the NHIS, comprises a household component (with data from individual 
households and their members and supplemented by data from medical provider) and 
includes an additional insurance component (survey of employers that provide data on 
employer-based health insurance). The household component provides information on 
use and access of medical services, prescribed medicine and health insurance coverage. 
The insurance component collects information regarding the financing of health 
expenditures through an establishment survey and a health insurance survey in the private 
and state governments sectors.  
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CHAPTER IV 
DISCUSSION 
Key findings  
Differences between PA and GA regarding state initiatives that address the needs 
of individuals with ASD go beyond the characteristics of their insurance mandates. 
Chronologically, GA was the first one to provide services that would reach the ASD 
population with the implementation of BCW in 1987 and H.B. 565 in 2001. However, 
GA’s efforts slowed down in the 2000’s even when the first ASD insurance policies 
began to pass in other states.  Meanwhile in PA, the creation of a The Autism Task Force 
in 2003 triggered a consistent development of programs, surveillance and policies. Thus, 
the current study shows that the presence of less state-driven health-related initiatives that 
target children and adolescents with ASD may tend to coexist with delays in the passage 
of an ASD insurance mandate and the inclusion of more conservative provisions in the 
bill.     
In the review of the ASD insurance mandates, an existence of important 
differences in PA’s and GA’s current bills were detected. Individuals may not be covered 
when in self-insured or small business health plans in PA and when under Medicaid or 
over 6 years of age in GA. Nonetheless, the present case study indicated that both bills 
address crucial pieces of the management of ASD symptoms, especially behavioral 
services (including Applied Behavioral Analysis). Many insurance companies have 
labeled those services as “experimental” and excluded them from coverage (Hansel, 
2013). Yet, an intensive and comprehensive behavioral treatment, especially during early 
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childhood, drastically improves the actions and skills of individuals with ASD through 
their lives (LeBlanc & Gillis, 2012). Behavioral therapy accounts for a good portion of 
the out-of-pocket medical expenditure for parents of children and adolescents with ASD, 
which is closely related with health-insurance coverage (Parish, 2015).  
In this case study, there was no evidence that the data sources reviewed provide 
comprehensive indicators that can be used to analyze the impact of insurance policies in 
PA or GA. In particular, there were larger gaps in indicators for ASD-related exams and 
behavioral therapies, which could compromise the measurement of health-related 
outcomes associated with those healthcare services. The cost of care indicator could only 
be tracked in detail in less than half of the data sources, which could compromise the 
assessment of the economics of the insurance mandates. Furthermore, many data sources 
were limited because of the specific settings in which the data were collected (ambulatory 
care, physician’s office, etc.). Therefore, this case study indicates an urgent need for data 
collection systems at the state level that can appropriately represent children and 
adolescents with ASD and that can also assess the impact of insurance policies and 
programs among this population.  
Implications and recommendations 
Based on the findings from this case study, the selected states could benefit from 
a different set of recommendations due to discrepancies in their mandates’ provisions and 
implementation. For example, through this evaluation of data sources, PA could better 
understand the type of insurance plans, the utilization of services and drugs, and the cost 
of treatment among children and adolescents with ASD. To date, there is only one study 
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that evaluated the impact of the ASD mandate in PA (Stein et al., 2012). Stein et al., 2013 
used claims data from a managed behavioral health organization to understand the 
changes in the service utilization among Medicaid enrollers after Act 68. PA will be able 
to focus their efforts on addressing these specific gaps in the available data sources by 
addition specific questions regarding service utilization, drugs prescription, and cost of 
care in the Autism Census Project. Until those gaps are addressed, many questions 
regarding the effects and appropriateness of the policy in the entire ASD community of 
PA will remain unanswered.  
GA could use the findings from this case study in a differently manner. For 
example, GA can utilize the data sources reviewed in the present study to better 
understand the demand for healthcare and the trends in the treatment for ASD. This is 
especially critical given that GA just passed (April, 2015) an ASD insurance bill. Thus, 
GA has an opportunity to revise indicators so that an evaluation of the insurance policies 
could be properly conducted. The present study may also contribute to intensifying the 
demand for a state-level strategic plan for ASD and for initiatives that address the health 
needs of children and adolescents with ASD in GA. The Metropolitan Atlanta 
Developmental Disabilities Surveillance Program (MADDSP) was a CDC initiative that 
focused on estimating the prevalence of developmental disabilities, including ASD, and 
served as the model for creation of ADDM Network in the U.S. GA could utilize some 
features of the methodology of this surveillance system to create a state service that 
tracks the policy-related indicators as additional measures of interest. MADDSP 
identifies children who are or will turn 8 years of age within the year of interest through 
an active record review at multiple health and education sources. Intending to understand 
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the individuals with ASD and their specific healthcare needs and treatment trends in 
Georgia, the proposed state-driven surveillance system could be collecting variables to 
address the gaps in the current data sources.  
The present case study can also serve as a model to evaluate policy tracking and 
health-related impact of ASD insurance policies among children and adolescents with 
ASD in other states. A similar analysis could be replicated in other states, considering 
that little evidence exists regarding the effectiveness of ASD insurance laws on 
improving health outcomes in the target population. Tracking the impact of existing state 
policies and programs is crucial to continue to improve the discussion regarding the best 
practices for the management of ASD. States play a central role in the prediction of cost 
savings and long-term consequences of their initiatives and should utilize this case study 
in their process of building those predictions. 
Limitations of the case study  
 It is important to note some limitations of this case study that could implicate the 
quality of the findings and the ability to reach the study objectives more effectively. First, 
the study did not review programs delivered by non-governmental entities in PA and GA 
that could also affect the service utilization and assist in the surveillance for individuals 
with ASD. Even though the study focused on state-regulated initiatives, the knowledge 
about those other resources could have provided a more accurate picture of initiatives 
available for children and adolescents with ASD in PA and GA. Furthermore, the current 
study did not examine specific measures used to track indicators of the insurance 
mandates in the data sources that were reviewed. Future studies can take a more granular 
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examination of the indicators and specific measures as outlined in CDC Best Practices for 
Evaluation (CDC, 1999). While it is a limitation it is also fodder for future efforts to 
properly examine the effectiveness of state-level mandates on ASD coverage.  
Lastly, the study did not address the possible impact of some federal initiatives 
that focus on children and adolescents with ASD and that include provisions that are 
mandated in states. The Autism Collaboration, Accountability, Research, Education and 
Support (CARES) Act (2014) reauthorizes the Combating Autism Act (2006) and 
dedicates resources for research, surveillance, and services for individuals with ASD in 
all age groups (Williams, 2014). The Achieving a Better Life Experience (ABLE) Act 
(2014) enacted a tax-free savings account for individuals with disabilities; the Act serves 
as a supplemental program to private insurance and Medicaid (NDI, n.d.). The Autism 
Care Demonstration (ACD) (2014) guaranteed the coverage of applied behavioral 
analysis services for individuals with ASD enrolled in TRICARE health plans 
(TRICARE, n.d.). Lastly, the Affordable Care Act (ACA), fully implemented in 2014, 
includes requirements to improve access and affordability of healthcare for individuals 
with ASD (Autism Speaks, n.d).   
Conclusion  
Despite some of the stated limitations, the present study is an important resource 
for state public health agencies and public health researchers because of novelty in 
assessing indicator tracking for public health policy and a review of available data 
sources for evaluation purposes. The data Quality Campaign (2010) highlights the 
importance of connecting policy and data, indicating that states “…need to prioritize and 
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elucidate the critical questions and issues that data systems must answer.” Furthermore, 
this study’s review of policies, programs, and the data sources was the result of 
collaboration between important stake holders, such as health and government agencies, 
non-profit organizations, and universities that are intensively involved in the discussions 
regarding ASD insurance coverage and related outcomes in the selected states. Finally, 
the case study also provides key short and long-term recommendations to states that 
could impact the management of the ASD-related challenges in those settings  
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